NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
148 trialsNCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03091192 2026-01-23
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05432232 2025-12-02
CAIN
HistoSonics, Inc.
Phase NA Completed
NCT05696444 2025-11-25
Medtronic Hugoâ„¢ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
Phase NA Active not recruiting
NCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT04513522 2025-07-11
CheckMate 7C9
Bristol-Myers Squibb
Phase 4 Completed
NCT02821793 2025-07-01
PRIORITY
Institut Bergonié
Completed
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT03024437 2025-03-20
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
Phase 1/2 Terminated
NCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04489771 2025-02-11
MK-6482-013
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03138512 2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3 Completed
NCT03354390 2024-12-03
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT05363072 2024-10-01
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
Pfizer
Completed
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02431676 2024-08-28
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03311334 2024-04-18
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT01117779 2024-01-19
TRACE
Boston Scientific Corporation
Terminated
NCT04021238 2023-11-13
Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00496756 2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Phase 2 Terminated
NCT00003102 2023-10-04
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT01164228 2023-06-15
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01732120 2023-05-19
Off Clamp Randomization
Washington University School of Medicine
Phase NA Completed
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT02019693 2023-03-21
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03428217 2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT03387514 2022-12-21
UW17104
University of Wisconsin, Madison
Phase 2 Terminated
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT00199875 2022-10-10
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00199888 2022-10-10
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT01034631 2022-07-11
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT00392821 2022-06-06
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT02315066 2022-04-21
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Phase 1 Completed
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00003656 2022-03-18
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
Weill Medical College of Cornell University
Phase 2 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT01218555 2022-01-27
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
Phase 1 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01896271 2021-08-23
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT02118337 2021-06-01
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
MedImmune LLC
Phase 1/2 Completed
NCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated